Regeneron acquires bankrupt 23andMe for $256M, taking over its DNA database and services while pledging to uphold privacy ...

Genetic testing company 23andMe is being acquired, shortly after it declared bankruptcy months ago.

Biotechnology leader Regeneron Pharmaceuticals is acquiring genetic testing firm 23andMe for $256 million following its bankruptcy filing. The deal excludes 23andMe’s telehealth subsidiary, Lemonaid ...

Regeneron Pharmaceuticals has agreed to acquire the assets of bankrupt genetic testing company 23andMe for $256 million. Regeneron pledged to "ensure compliance with 23andMe's consumer privacy ...

Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, ...

In March, 23andMe said that it was looking to sell “substantially all of its assets” through a court-approved reorganization plan.

The DNA testing company would sell for a fraction of its peak valuation of $6 billion to a biotech aiming to use its data ...

After resigning as CEO of 23andMe, founder Anne Wojcicki said she is interested in buying the company back. One reason for doing so is the value of 23andMe’s data. “That data for 23andMe is ...

23andMe founder Anne Wojcicki has also expressed interest in buying back the company. During the hearing, attorneys representing a class of more than 6 million customers affected by the 2023 data ...

The sale of the bankrupt DNA data bank 23andMe is facing delays as the ... The former Silicon Valley startup co-founded by Anne Wojcicki has been negotiating with potential buyers trying to ...